[1]
M. Kamil, M. et al. 2023. Immunogenicity of the biosimilar CT-P13 infliximab or the original infliximab in Iraqi patients with Ankylosing spondylitis does not correlate with their demographic characteristics. Journal of the Faculty of Medicine Baghdad. 64, 4 (Jan. 2023), 261–267. DOI:https://doi.org/10.32007/jfacmedbagdad.6441969.